EU/3/05/261

Table of contents

About

On 7 March 2005, orphan designation (EU/3/05/261) was granted by the European Commission to Bausch & Lomb (UK) Ltd, United Kingdom, for fluocinolone acetonide (prolonged-release intravitreal implant) for the treatment of non-infectious uveitis affecting the posterior segment of the eye.
The sponsorship was transferred to Bausch & Lomb Ireland in October 2006.

Key facts

Active substance
Fluocinolone acetonide (prolonged-release intravitreal implant)
Disease / condition
Treatment of non-infectious uveitis affecting the posterior segment of the eye
Date of first decision
07/03/2005
Outcome
Positive
EU designation number
EU/3/05/261

Sponsor's contact details

Bausch & Lomb Ireland
IDA Industrial Park
Waterford
Ireland
Telephone: + 353 51 35 501
Telefax: + 353 51 35 56 39
E-mail: waterfordinfo@bausch.com

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

How useful was this page?

Add your rating
Average
2 ratings